Blueprint Medicines Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Blueprint Medicines

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (5)	11/16/2018 10:39:40 AM
From: tuck	Read Replies (1) of 12

Recall that in 2nd line GIST, BPMC will have to use ctDNA to find the subset for which avapritinib works (apart from the D842V mutation present in 5% of GIST population). From their PR: "analyses of circulating tumor DNA (ctDNA) from the NAVIGATOR trial across all lines showed increased activity for avapritinib in patients without the secondary KIT V654A or T670I mutations, which are estimated to occur in about 20 to 25 percent of GIST patients following treatment with imatinib." So the addressable 2L market is 75% of the total. But . . Detectability of ctDNA for GIST not good You may have to upsize the tweet to see the image, but it is showing GIST ctDNA as detectable in only ~20% of patients (I couldn't find the GIST bar in the publication referenced by the slide, however). A more recent publication found ctDNA in half of pretreated patients (small n, though), which still isn't going to make an oncologist order the test versus prescribing a more broad spectrum drug such as DCPH's. Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor Does BPMC have any shot at 2nd line? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next